The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
Johnson & Johnson reported positive Phase 2 results for its drug nipocalimab in treating systemic lupus erythematosus and Sjögren's disease. Following this, the company acquired biotech firm Firefly Bio in a $1 billion cash deal to expand into KRAS-targeting degrader conjugates. Other significant industry activity included Incyte's $2 billion purchase of Vega Therapeutics and Galmed Pharmaceuticals' acquisition of Colospan to focus on gastrointestinal medical technology.